Amgen Inc. Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)
Amgen Inc. (AMGN) had Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) of -$217.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease · last filed 2026-08-05
- 2026-06-30: Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) -$217.00M.
- 2026-03-31: Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) -$183.00M.
- 2025-12-31: Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) -$161.00M.
- 2025-09-30: Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) -$159.00M.
| Period end | Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) | Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) as first filed |
|---|---|---|
| 2026-06-30 | -$217.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | -$183.00M 10-Q · filed 2026-05-01 | |
| 2025-12-31 | -$161.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | -$159.00M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$186.00M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | -$247.00M 10-Q · filed 2025-05-02 | |
| 2024-12-31 | -$343.00M 10-K · filed 2026-02-13 | |
| 2024-09-30 | -$192.00M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | -$345.00M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | -$363.00M 10-Q · filed 2024-05-03 | |
| 2023-12-31 | -$314.00M 10-K · filed 2025-02-14 | |
| 2023-09-30 | -$494.00M 10-Q · filed 2023-10-31 | |
| 2023-06-30 | -$436.00M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | -$343.00M 10-Q · filed 2023-04-28 | |
| 2022-12-31 | -$437.00M 10-K · filed 2024-02-14 | |
| 2022-09-30 | -$450.00M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | -$210.00M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | -$53.00M 10-Q · filed 2022-04-28 | |
| 2021-12-31 | $284.00M 10-K · filed 2023-02-09 | |
| 2021-09-30 | $371.00M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $424.00M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $391.00M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $566.00M 10-K · filed 2022-02-16 | |
| 2020-09-30 | $643.00M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $678.00M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $648.00M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $296.00M 10-K · filed 2021-02-09 | |
| 2019-09-30 | $391.00M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $295.00M 10-Q · filed 2019-07-31 | |
| 2019-03-31 | -$77.00M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | -$53.00M 10-K · filed 2020-02-12 | $53.00M 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |